RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Recruiting
Observational Study
Radiomic
Radiomics
Breast Cancer Metastatic
Breast Cancer Stage IV
Breast Carcinoma
Breast Neoplasms
Breast Cancer
Breast Cancer With Bone Metastasis
Breast Cancer With Metastatic Bone Disease
Trastuzumab
HER2
HER2 + Breast Cancer
HER2 Positive Breast Carcinoma
HER2-positive Breast Cancer
Her2/Neu Positive Advanced Solid Tumors
HER2/Neu-positive Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal hete…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024.
Exclusion Criteria:
* Not available imaging (CT scan and/or PET-FdG scan) in the three months before the biopsy or before …
Contacts